10-48174919-C-T
Position:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_001018071.4(FRMPD2):c.3026G>A(p.Cys1009Tyr) variant causes a missense change involving the alteration of a non-conserved nucleotide. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.0000083 ( 0 hom., cov: 14)
Exomes 𝑓: 0.000085 ( 0 hom. )
Consequence
FRMPD2
NM_001018071.4 missense
NM_001018071.4 missense
Scores
1
2
16
Clinical Significance
Conservation
PhyloP100: 2.64
Genes affected
FRMPD2 (HGNC:28572): (FERM and PDZ domain containing 2) This gene encodes a peripheral membrane protein and is located in a region of chromosome 10q that contains a segmental duplication. This copy of the gene is full-length and is in the telomeric duplicated region. Two other more centromerically proximal copies of the gene are partial and may represent pseudogenes. This full-length gene appears to function in the establishment and maintenance of cell polarization. The protein is recruited to cell-cell junctions in an E-cadherin-dependent manner, and is selectively localized at the basolateral membrane in polarized epithelial cells. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.14411518).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
FRMPD2 | NM_001018071.4 | c.3026G>A | p.Cys1009Tyr | missense_variant | 24/29 | ENST00000374201.8 | |
FRMPD2 | NM_001318191.1 | c.2951G>A | p.Cys984Tyr | missense_variant | 22/27 | ||
FRMPD2 | NM_001042512.3 | c.59G>A | p.Cys20Tyr | missense_variant | 1/6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
FRMPD2 | ENST00000374201.8 | c.3026G>A | p.Cys1009Tyr | missense_variant | 24/29 | 1 | NM_001018071.4 | P2 |
Frequencies
GnomAD3 genomes AF: 0.00000832 AC: 1AN: 120262Hom.: 0 Cov.: 14
GnomAD3 genomes
AF:
AC:
1
AN:
120262
Hom.:
Cov.:
14
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000503 AC: 3AN: 59640Hom.: 0 AF XY: 0.0000668 AC XY: 2AN XY: 29942
GnomAD3 exomes
AF:
AC:
3
AN:
59640
Hom.:
AF XY:
AC XY:
2
AN XY:
29942
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000849 AC: 47AN: 553426Hom.: 0 Cov.: 6 AF XY: 0.000125 AC XY: 37AN XY: 295994
GnomAD4 exome
AF:
AC:
47
AN:
553426
Hom.:
Cov.:
6
AF XY:
AC XY:
37
AN XY:
295994
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000831 AC: 1AN: 120346Hom.: 0 Cov.: 14 AF XY: 0.0000176 AC XY: 1AN XY: 56764
GnomAD4 genome
AF:
AC:
1
AN:
120346
Hom.:
Cov.:
14
AF XY:
AC XY:
1
AN XY:
56764
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ExAC
AF:
AC:
1
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 23, 2023 | The c.3026G>A (p.C1009Y) alteration is located in exon 24 (coding exon 24) of the FRMPD2 gene. This alteration results from a G to A substitution at nucleotide position 3026, causing the cysteine (C) at amino acid position 1009 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T;T;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T;T;T
M_CAP
Benign
T
MetaRNN
Benign
T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
.;N;.
MutationTaster
Benign
D;N;N;N
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
.;D;D
REVEL
Benign
Sift
Benign
.;T;T
Sift4G
Benign
.;T;T
Polyphen
1.0, 1.0
.;D;D
Vest4
0.18, 0.20
MutPred
Gain of methylation at K1014 (P = 0.0972);Gain of methylation at K1014 (P = 0.0972);.;
MVP
0.30
MPC
2.6
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at